BioCryst Pharma (BCRX) Tops Q3 EPS by 8c
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
BioCryst Pharma (NASDAQ: BCRX) reported Q3 EPS of ($0.16), $0.08 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $5.94 million.
Cash, cash equivalents and investments decreased to $68.7 million at September 30, 2016, as compared to $100.9 million at December 31, 2015. Net operating cash use for the third quarter of 2016 was $15.0 million, as compared to $12.3 million for the third quarter of 2015.
Financial Outlook for 2016
Based upon development plans and the Company’s awarded government contracts, BioCryst continues to expect its 2016 net operating cash use to be in the range of $55 to $75 million, and has revised its 2016 operating expenses to be in the range of $68 to $80 million, which reflects a reduction from the previous forecasted range of $78 to $98 million. BioCryst’s operating expense range excludes equity-based compensation expense due to the difficulty in reliably projecting this expense, as it is impacted by the volatility and price of the Company’s stock, as well as the vesting of the Company’s outstanding performance-based stock options.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vera Bradley (VRA) Tops Q3 EPS by 1c; Offers Light Q4 Outlook; Enters New Licensing Agreements
- Toll Brothers (TOL) Posts Improved Q4 Adjusted Pre-Tax Income
- Bob Evans Farms (BOBE) Tops Q2 EPS by 11c; FY17 adj.-EPS Outlook Boosted
Create E-mail Alert Related CategoriesEarnings, Guidance
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!